Gene Therapy & Gene Editing Deal Benchmarks

Median Upfront

$88M

Range: $41M - $135M

Total Deal Value

$864M

Range: $475M - $1.3B

Royalty Rate

8.5% - 14.9%

Tiered up to 18.9%

Dev Milestones

$310M

Range: $174M - $447M

Model Your Deal

Market Analysis

Gene therapy and gene editing platforms are attracting transformative licensing deals across oncology and rare disease. Phase 1 gene therapy deals carry a median total deal value of $864M, with upfront payments ranging from $41M to $135M. The high valuations reflect the one-time curative potential and breakthrough therapy designations frequently granted to these approaches.

Development milestones account for $310M in a typical gene therapy deal, reflecting the extensive clinical de-risking required around durability of expression, immunogenicity management, and manufacturing consistency of viral vectors. Regulatory milestones ($272M) and commercial milestones ($194M) complete the value stack.

Royalty rates for gene therapy span 8.5% to 14.9% at the base tier. The unique pricing dynamics of curative one-time therapies -- often priced at $1M+ per patient -- create distinctive commercial milestone structures where sales thresholds must account for small patient populations but high per-patient revenue.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What are typical deal terms for gene therapy licensing?

Phase 1 gene therapy deals average $88M upfront with $864M total deal value. The 10/90 upfront/milestone split reflects early-stage risk and the high de-risking potential of successful clinical data.

How do gene editing deals differ from AAV gene therapy deals?

Gene editing platforms (CRISPR, base editing, prime editing) often command platform premiums due to their programmable nature and potential for multiple indications. AAV-based gene therapies are more established clinically but face challenges with re-dosing and manufacturing. Both carry similar total deal values at equivalent stages.

What risks affect gene therapy deal valuations?

Key risks include durability of gene expression, immunogenicity of viral vectors, manufacturing scalability and consistency, high treatment costs creating payer resistance, and competition from emerging editing technologies. These risks are balanced by the curative potential and frequent breakthrough therapy designations.

What royalty structures are used in gene therapy deals?

Gene therapy royalties range from 8.5%-14.9% base, escalating to 18.9%. The one-time treatment model means commercial milestones are often structured around patient counts rather than traditional revenue thresholds.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Gene Therapy & Gene Editing Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

CAR-T Cell Therapy Deals

Preclinical Deal Benchmarks

Phase 2 Deal Benchmarks

Oncology Deal Overview 2026

Ready to Calculate Your Deal Terms?